Immutep
Immutep is a biotechnology company focused on developing LAG-3 related immunotherapy products for the treatment of cancer and autoimmune diseases. The company is pioneering the LAG-3 space and has clinical-stage assets targeting areas of high unmet need.
Short position
Immutep (ASX:IMM) has 1.07% of its shares on issue reported as short positions as of 5 Oct 2026, or about 15,826,532 shares. Over the past 30 days that figure has fallen 1.00 percentage points, and over 90 days it has fallen 1.38 percentage points. Its highest recorded short interest was 3.74% in July 2026. IMM is classified in the Pharmaceuticals, Biotechnology & Life Sciences industry. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.
Price & short interest
Toggle series, zoom, and compare · ASIC daily, T+4Immutep (IMM) short interest history
IMM Short Interest History
- 30-day change
- -1.00pp
- 90-day change
- -1.38pp
- 1-year change
- -1.47pp
- All-time high
- 3.74% (July 2026)
- All-time low
- 0.00% (March 2024)
Is IMM heavily shorted?
Not especially: 1.07% short interest is modest by ASX standards, ranking #234 of 799 ASX securities with reported short positions. ASIC requires positions of 0.01% of issued capital or $100,000 (whichever is less) to be reported.
How has IMM's short interest changed recently?
Over the past 30 days Immutep's short interest has fallen 1.00 percentage points, and over 90 days it has fallen 1.38 percentage points. The current level is 1.07% of shares on issue.
What is the highest IMM's short interest has been?
Since 2018, Immutep's short interest peaked at 3.74% in July 2026 and bottomed at 0.00% in March 2024.
Where does this data come from?
All figures are sourced from daily ASIC short position reports, published with a four trading-day (T+4) delay. Shorted aggregates the full history since 2018. See our methodology.